Markets & Investing
FILAMENT HEALTH ANNOUNCES TERMINATION OF PROPOSED BUSINESS COMBINATION WITH JUPITER ACQUISITION CORPORATION
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development…
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, today announced that the Business Combination Agreement, by and among the Company, Jupiter Acquisition Corporation (NASDAQ: JAQC) (“Jupiter“), 1427702 B.C. Ltd. (“TopCo“) and Filament Merger Sub LLC, dated as of July 18, 2023 (as amended by the First Amendment to the Business Combination Agreement, the “Business Combination Agreement“), with respect to a proposed business combination between Filament and Jupiter (the “Proposed Business Combination“), has been terminated by the parties by mutual agreement.
As previously announced in the Company’s press release dated December 18, 2023, the Company was required to make material changes to the terms of the Proposed Business Combination and the proposed financing of senior secured convertible notes by Helena Global Investment Opportunities 1 Ltd. (the “Note Financing“) in order to enable the combined company after the Proposed Business Combination to meet Nasdaq listing requirements.
Given the material changes required in order to meet Nasdaq listing requirements, the parties have determined not to continue to pursue the Proposed Business Combination and therefore have decided to terminate the Business Combination Agreement. Given that the completion of the Proposed Business Combination is a condition to closing the Note Financing, the Note Financing will not be completed at the present time.
ABOUT FILAMENT HEALTH CORP (OTCQB:FLHLF) (NEO:FH) (FSE:7QS)
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. We are paving the way with what we believe to be the first-ever natural psychedelic drug candidates.
Learn more at www.filament.health and on Twitter, Instagram and LinkedIn.
-
Law & Regulation1 week agoClearmind signs agreement with Hebrew University for psychedelic compound rights
-
Psychedelics1 week agoCybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
-
Psilocybin1 week agoCalifornia advances bill for psychedelics centers
-
Psilocybin4 days agoPassover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week agoPsychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics1 week agoRevive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
-
Psychedelics3 days agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics4 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID